Phosphorylase kinase (PhK) has been linked with a number of conditions such as glycogen storage diseases, psoriasis, type 2 diabetes and more recently, cancer (Camus S. et al., Oncogene 2012, 31, 4333). However, with few reported structural studies on PhK inhibitors, this hinders a structure based drug design approach. In this study, the inhibitory potential of 38 indirubin analogues have been investigated. 11 of these ligands had IC50 values in the range 0.170 -0.360 µM, with indirubin-3'-acetoxime (1c) the most potent. 7-bromoindirubin-3'-oxime (13b), an antitumor compound which induces caspase-independent cell-death (Ribas J. et al., Oncogene, 2006, 25, 6304) is revealed as a specific inhibitor of PhK (IC50 = 1.8 µM). Binding assay experiments performed using both PhK-holo and PhK-γtrnc confirmed the inhibitory effects to arise from binding at the kinase domain (γ subunit). High level computations using QM/MM-PBSA binding free energy calculations were in good agreement with experimental binding data, as determined using statistical analysis, and support binding at the ATP-binding site. The value of a QM description for the binding of halogenated ligands exhibiting σ-hole effects is highlighted. A new statistical metric, the 'sum of the modified logarithm of ranks' (SMLR), has been defined which measures performance of a model for both the "early recognition" (ranking earlier/higher) of active compounds and their relative ordering by potency. Through a detailed structure activity relationship analysis considering other kinases (CDK2, CDK5 and GSK-3α/β), 6'(Z) and 7(L) indirubin substitutions have been identified to achieve selective PhK inhibition. The key PhK binding site residues involved can also be targeted using other ligand scaffolds in future work.
Introduction
Many physiological processes in cells are controlled via reversible phosphorylation of target proteins through the activity of kinases and phosphatases. Dysfunction affects signal transduction and leads to numerous diseases such as cancer, neurodegenerative diseases and diabetes [1] .
Among the hundreds of kinases/phosphatases identified to date, phosphorylase kinase (PhK) plays a key role in the glycogen metabolism, catalyzing the phosphorylation of a single residue (Ser14) on glycogen phosphorylase b (GPb), creating its more active GPa state [2] . PhK is a large 1.3 MDa hexadecameric complex composed of four subunits (α, β, γ, δ). The γ subunit is the kinase domain (45 kDa) carrying the active site, the δ subunit is an endogeneous calmodulin conferring the calcium sensitivity, while the α and β subunits possess phosphorylation sites which regulate the activity of PhK. Genetic mutation on the genes coding for PhK induce severe disorders like glycogen storage diseases (i.e. VIII, IX and X) whereas physiological hyperactivity of the enzyme was shown to be linked with psoriasis [3, 4] . The highly specific activity of PhK also makes it a potential target for drugs involved in the control of the glucose metabolism, such as type 2 diabetes (T2D) [2, 5] . Recently, PhK has also been identified as a new potential target for development of anti-angiogenic therapies [6] . The structure of the PhK heterotetramer (αβγδ)4 has been determined to 9.9 Å resolution using cryo-electron microscopy single particle reconstruction [7] . While the kinase domain of PhK (PhK-γtrnc) has been expressed and crystallized together with nucleotides (ATP and ATP analogue, AMPPMP) and substrate analogues [2, [8] [9] [10] , until very recently this had not been achieved with inhibitors. In this regard, the crystal structure of the γ subunit of human PhK (hg2-PhK) in complex with sunitinib (pdb: 2Y7J) has been solved. This work has yet to be published, but this is the first successful crystallization of the γ-PhK catalytic site without the presence of ATP. Recently, also, we have refined using molecular dynamics the structure of PhKγtrnc in complex with two indirubin and two staurosporine derivatives [5, 11] .
Although kinase inhibitors have been discovered from various sources [12] [13] [14] [15] , the major obstacle to kinase-directed drugs is the cross-inhibition linked to their highly homologous ATPbinding sites [12] . Staurosporine, although too toxic for clinical use, is a potent inhibitor of PhK (Ki = 0.37 nM) [5] . However, its kinase activity is not specific to PhK [16] . Its analogue, KT5720, is a more specific inhibitor of PhK (Ki = 18.4 nM) and interactions leading to its specificity we have previously studied [5] . Meanwhile, competitive inhibitors from the indirubin family acting on CDKs and GSK-3 have been quite extensively studied [17] [18] [19] [20] but information on their activity towards PhK has been limited and has in part motivated the current study [5] . Indirubin (1a, Scheme 1) is a natural bis-indol molecule found in plants and mollusks [21] . It has demonstrated antileukemic properties, although the exact mechanism of this remains unclear [22] . Modifications of indirubin have lead to the discovery of other potential anticancer compounds [20, [22] [23] [24] . The indirubin family of compounds target several kinases, some of which have been co-crystallised with indirubin analogues: GSK3, CDK2, CDK5, PfPK5 [18, [25] [26] [27] [28] [29] [30] . Despite this apparent promiscuity towards kinases, through modification of the indirubin scaffold, kinase specific indirubin inhibitors can be designed. [18, 19] For example, an indirubin analogue over 4000 times more potent for GSK-3α/β compared to CDK1/cyclin B and CDK5/p25 has been reported [18] . In terms of PhK inhibition, we recently reported indirubin-3'-oxime (1b, Scheme 1) as a moderately potent inhibitor of PhK (IC50 = 144 nM) [5] . However, apart from this study, structure based design studies on PhK ATP-binding site inhibitor are limited. In light of recent results highlighting PhK inhibition from a therapeutic perspective [6] , there is an immediate need for new rational drug design efforts. Scheme 1. Indirubin (1a) and indirubin-3'oxime (1b) together with their IC50's for PhK-holo inhibition and whose binding at PhK was studied in detail in previous work [5] . Shown also are the hinge region hydrogen bonds as observed in MD studies [5] , which is the "expected binding mode" consistent with the binding of indirubins to other kinases [18, 25, 27, 29] . However, a recent study for the binding of indirubins at DYRK kinases, revealed that an "inverse binding mode" is also possible [30] . L, W, X, Y and Z represent the substitution positions of the 38 indirubin analogues studied in this work (Table 1) , while substitution of the hydrogen on N1 with methyl was also explored.
In the current study, the binding potential (IC50's) of 38 indirubin derivatives (shown in Table 1 ) against PhK has been studied. Experiments using both the truncated catalytic site (PhKγtrnc) and holoenzyme (PhK-holo) for 5 of these analogues suggest that the inhibitors target the γ- 1a Indirubin IC 50 = >50 µM 1b Indirubin-3oxime
subunit. Accordingly, exploiting our previously refined MD structure of PhK-γtrnc in complex with indirubin-3'-oxime [5] , we have performed extensive modelling calculations in the form of Glide molecular docking followed by more advanced Quantum Mechanics/Molecular Mechanics (QM/MM) and QM/MM-PBSA (Poisson Boltzmann Surface Area) computations [31] to better understand the binding mechanisms at the PhK ATP-binding site. The performance of the computational models are compared by statistical analysis, for which we defined a new metric, the 'sum of the modified logarithm of ranks' (SMLR). Finally, the activity and potential selectivity of indirubin analogues towards PhK inhibition is thoroughly analysed via structure activity relationship (SAR) analysis. The predicted thermodynamics of binding from the QM/MM-PBSA calculations and binding data (structural and activity) for homologous kinases is considered for this purpose.
MATERIALS & METHODS
Protein production: The holoenzyme of PhK from fast-twitch skeletal muscle of female New
Zealand White rabbits was purified by the modified method of Cohen [32] as described in VenienBryan et al. [33] . PhK-γtrnc was expressed as an N-terminal Glutathione-S-Transferase (GST) fusion [5] . Rabbit muscle GPb was purified according to Fischer and Krebs [34] . The concentrations of GPb and PhK were determined from absorbance measurements at 280 nm using extinction coefficients ε 1% 1cm =13.2 [35] and ε 1% 1cm =12.4 [36] , respectively. PhK-γtrnc concentration was determined according to Bradford [37] .
Synthesis of indirubins:
The 38 indirubin analogues were prepared and characterized according to methods we have described previously [18, 38] .
IC50 measurements:
The enzymatic activities of PhK-holo and PhK-γtrnc were measured by monitoring the conversion of glycogen phosphorylase b (GPb) to GPa by assaying phosphorylase activity in the presence of 10 µM AMP and 0.5 mM caffeine in the direction of glycogen synthesis [2, 39] . In the presence of inhibitors, activities were assayed at constant concentrations of GPb (1 mg/ml) and ATP (50 μΜ 
Ligand binding free energies were also calculated using QM/MM-PBSA with Eq. (2), the foundations of which we have described before [44] .
For these calculations, therefore, re-ranking of protein-ligand binding conformations from docking was performed and a more theoretically rigorous estimate of relative activities obtained. All calculations employed DFT with the M06-2X functional [45] and the all electron MIDIX basis set [46, 47] was used for the QM region (the ligands), previously shown to be effective for halogen substituted ligands in studies of this type [48] . The PhKγ-trnc protein was described using MM with the OPLS-AA(2005) forcefield [49] . No cut-off for non-bonded interactions was employed.
Effectively, the MM region polarizes the QM region, with electrostatic interactions between the MM point charges and the QM wavefunction, and van der Waals interactions between QM and MM atoms accounted for [50] . Bulk solvation effects were included using PBSA [51] , allowing [31] . RRHO calculations were performed using MacroModel 9.9 [31] . analyzed in a statistical manner [52, 53] . Several performance metrics were considered including the basic hit-rate to those that better highlight "early recognition" (the ranking of actives early/higher in an ordered list). The hit-rate used is a simple metric which represents the % of real actives in the predicted top ranked n ligands, where n is the number of actives. A receiver operator characteristic (ROC) plot shows the relationship between the true positive rate (TPR, or sensitivity) and the false positive rate (FPR, or specificity), with the Area Under the ROC curve (AU-ROC) a common way to summarize the overall quality of a ROC plot:
Statistical Analysis of Binding Predictions
where fi is the fraction of non-actives ranked higher than the ith active. AU-ROC varies between 0 and 1, where 0.5 corresponds to a random ranking and 1 meaning that all actives are ranked above the inactives. The AU-ROC values, however, do not distinguish early and late performance [52] . Accordingly, we also used the "sum of logarithms of ranks" (SLR) metric [53] which accounts for "early recognition" of actives and which we defined as [54, 55] :
where ri is the rank of the ith active among N total compounds, and the negative logarithm emphasizes early recognition.
To further extend the "early recognition" SLR metric to reward for the correct ordering of actives by their known IC50's, assigning greater weight to the more active compounds, we have defined a new metric, the "sum of the modified log ranks" (SMLR). If r = [r1,r2, …., rn] is the vector of ranks of the n actives and they are ordered by their inhibition constants, with r1 the most active, the SMLR value is calculated:
. (5) The denominator in the expression requires the addition of the square root of the total number of compounds, to ensure the quotient always lies between 0 and 1. Thus, the negative of the log produces values of the same polarity.
In an ideal situation, all actives will be ranked in the first n positions for an optimal SLR value and additionally ranked according to potencies for SMLR. The worst scenario is when all the n actives are ranked sequentially from N -n +1 to N (for SLR) and additionally in reverse order of potency (for SMLR). This allows us to calculate theoretical "minimum" and "maximum"
SLR and SMLR values, and normalized SLR and SSLR values according to:
The metric values can therefore range from 0 to 1, with 1 being the ideal situation.
The null distributions of (N)SLR and (N)SMLR were obtained through a simulation procedure. Under the null hypothesis, ranks of active molecules are the result of random assignment across all possible ranks. The empirical random ranking distributions were simulated using a bespoke function by repetitively drawing ranks from a uniform distribution over time. 1 million repetitions has been advocated elsewhere [53] , and was applied in this study. Simulations were performed using the statistical software program R [56] . The null distributions can be used as probability distributions, where the relative positions of the actual values of (N)SLR and (N)SMLR on these distributions converts to a probability. Since there were no tied ranks amongst the predictions, random drawing of ranks was done without replacement to imitate reality. Where there were tied values of experimental IC50's, the ranking of the ties was determined by using their relative predicted ranking. 
RESULTS AND DISCUSSION
Binding Assay Experiments: Although PhK carries its kinase catalytic activity only on its γ subunit, other nucleotide-binding sites have been reported on other subunits of the holoenzyme.
The presence of several sites can be justified by two other nucleotide-dependent activities linked to the enzyme: autophosphorylation [57] and ATPase [58] although no definite relationship has yet been detected between the sites and the activities. At least one adenine nucleotide-binding site has been reported on each of the large regulatory subunits [59] [60] [61] .
The full set of IC50 results for the 38 indirubins using PhK-holo calculated from doseresponse curves ( Figure 1 ) are shown in Table 1 . For comparison, the corresponding IC50 values for CDK1/cyclin B, CDK5/p25 and GSK-3α/β inhibition are also shown [18, 20, 62] . 21 of the 38 inhibitors had IC50's ≤ 10 µM for PhK-holo inhibition with the best of these having IC50's ~ 0.2 [18, 20, 62] . µM. The inhibition constants of some of the most potent indirubin analogues (1b, 1c, 1d, 4b, 4c) were also determined for PhK-γtrnc (Table 2) , where the similarity of the IC50 values for both
PhK-holo and PhK-γtrnc implies that the indirubin analogues target the γ subunit. (6)). It does this by reducing relative to SLR, the weight of the predicted rank through its square root and taking into account the actual rank through addition. There are many potential metrics which can be devised to account for the correct relative ordering amongst actives. SMLR was used since it is functionally similar to SLR, and it seems to behave reasonably. To illustrate this, a set of situations comparing NSLR and NSMLR values for different hypothetical predicted ranking of actives are given in the Supporting Information (Tables S1-S2 ). replicating the situation in the current study, a retrospective analysis of a smaller set of compounds with a much greater ratio of actives ( � ), the corresponding distributions for n = 21 and n = 11 within a set of N = 38 compounds is shown. We can see that the NSMLR distribution is similar to that of NSLR, which derives from a gamma distribution (SLR) [53] . With greater � ratios such as for Actives 1 and Actives 2, as expected, there is a higher probability of a prediction matching random. This is reflected in the greater spread of the NSLR and NSMLR values in the null distributions compared to the case of n = 10 in a set of N = 1000. However, the distributions allow us to produce probabilities (p-values) which reflect the robustness of the predictions and therefore entirely validate the statistical significance of the � ratios used in the current study. Further comparisons of the null distributions for the different � ratios are including in the Supporting Information ( Figures S1 and S2 ). AU-ROC has been reported as independent of the ratio of actives [63] , although this has been questioned and refuted in recent studies [52] . An associated problem is that when studies are performed with different ratio of actives, the values cannot be compared [52] . Our comparisons, however, are exempt from these problems, with all comparisons between values considering the same ratio of actives throughout.
The statistical performance metrics for the identification and ranking of active compounds obtained for the different docking and post-docking methods are displayed in the flowchart of Table 3 and the predicted binding of the most potent indirubin-3'-acetoxime (1c) ligand shown in Figure 5 . Ligands in Table 3 Glu153 and Asp167 residues which is partially occupied by the acetoxime ligand substituent.
To allow us consider the significant issue of kinase selectivity, inhibition data for CDK1/cyclin B, CDK5/p25 and GSK-3α/β kinases from previous work is also shown in Table 1 .
Although the IC50 values were determined using different assays, in each case the ATP concentration used was less than the KM for ATP (70 µM). In any case, we are comparing magnitudes of IC50 values through ratios (factors of the differences between potencies), rather than the actual values. Inhibition data for 34 of the 38 indirubins is included, allowing for a detailed analysis. The key PhK-γtrnc catalytic site residues for indirubin binding (MD model of indirubin-3'-oxime (1b) bound at the ATP-binding site [5] ) are shown in Figure 6 (A), together with the corresponding residues in the crystal structures of indirubin-3'-oxime (1b) bound GSK-3β [29] , indirubin-3'-oxime (1b) bound CDK5/p25 [27] , and indirubin-5-sulphonate bound CDK2/cyclin A [25] . Structural alignment of the PhK active site residues with those in CDK2, CDK5 and GSK-3β are shown in Figure 6 (B) as calculated using the program PDBeFold [71] . We note that the binding data for indirubins in Table 1 was obtained using CDK1/cyclin B rather than CDK2 for practical purposes [18, 20, 62] . However, CDK1 and CDK2 differ by only two amino acids in the ATP binding site, and CDK1 inhibitors were found to be equally active for CDK2 [18] . For the purposes of the below analysis, therefore, CDK1 and CDK2 will be discussed in the same light.
All ligands except 6-bromo-5-nitroindirubin-3'-oxime (12b), 7-bromoindirubin- While a Y acetoxime group is less favoured by the CDKs and GSK-3α/β compared to a favoured oxime substituent, acetoxime is in fact slightly favoured over oxime for PhK inhibition.
1c was the most potent indirubin for PhK inhibition identified in this work and its predicted binding is shown in Figure 5 . The acetoxime (-NOAc) methyl group partially occupies a space of negative ESP created by Glu153 O, and the Glu110 and Asp167 sidechain carboxylates. Rational inhibitor design would indicate that this pocket can be exploited to increase ligand potency, assuming that the desolvation energy cost does not out-weigh the enthalpy gains from any extra contacts formed [44] . In terms of kinase selectivity, we note that the corresponding aligned "e" residue ( Figure   6 (A)) to the PhK Glu110 from the triad is Asp for CDK2 and CDK5, and Thr in the case of GSK- Finally, a significant finding came from our analysis of position 7 (L) substitutions. While a 7-Br substitution decreases the potency of PhK inhibition, the effect is only minor compared to the negative effects on CDK1/cyclin B, CDK5/p25 and GSK-3α/β inhibition. 7-bromoindirubin-3'-acetoxime (13c) has an IC50 of 10 µM for PhK inhibition, but is inactive (> 100 µM) for the other kinases. Meanwhile, 7-bromoindirubin-3'-oxime (13b) has been revealed as important antitumour agent triggering the activation of non-apoptotic cell death, although the exact mechanism has yet to be determined [20, 62] . Interesting, therefore, 13b exhibits an IC50 of 1.8 µM with PhK, a factor of 12-18 times more potent than with CDK1/cyclin B (IC50 = 22 µM), CDK5/p25 (IC50 = 33 µM) and GSK-3α/β (IC50 = 32 µM). Indeed, a weak and gradually decreasing inhibition of CDK1, CDK5 and GSK-3α/β has been reported with different 7-halogeno-indirubin-3'-oximes when the size of the 7-atom substitution was increased [62] . This is suggestive of steric hindrance with the "c" aligned residues (Figure 6(A) ). The residue of significance is a leucine (Leu132) in the case of GSK-3α/β, with the IC50 of indirubin-3'-oxime (3b) decreasing by a factor of almost 1500 from 0.022 µM to 32 µM for 7-bromoindirubin-3'-oxime (13b). For PhK, CDK2 and CDK5, the corresponding residue is phenylalanine. Analysis of the distances in the CDK2 and CDK5 PDB structures used in Fig PhK are to date limited [5] . Recent findings highlight even more the need for new studies on
